No abstract

No abstract

We present the first limits on the Epoch of Reionization 21 cm H I power spectra, in the redshift range z=7.9-10.6, using the Low-Frequency Array (LOFAR) High-Band Antenna (HBA). In total, 13.0 hr of data were used from observations centered on the North Celestial Pole. After subtraction of the sky model and the noise bias, we detect a non-zero 56 13 mK D < ( ) at k=0.053 h cMpc −1 in the range z=9.6-10.6. The excess variance decreases when optimizing the smoothness of the direction-and frequency-dependent gain calibration, and with increasing the completeness of the sky model. It is likely caused by (i) residual side-lobe noise on calibration baselines, (ii) leverage due to nonlinear effects, (iii) noise and ionosphere-induced gain errors, or a combination thereof. Further analyses of the excess variance will be discussed in forthcoming publications.

The delay in diagnosis and treatment of breast cancer remains a serious problem. Several psychological and behavioural patient attributes strongly determine both patient-related delay time and system-related delay time, but their strength is different in particular countries.

This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC.

Activity and safety of FOLFOX4 plus either cetuximab administered weekly or every second week were similar.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints.

These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.